Earnings Reportpositive
Earnings Report
- Company
- ImmunityBio, Inc. (IBRX)
Other upcoming events for IBRX
Phase 2 StartPhase 2 Start: Phase 2, Randomized, Open-Label Clinical Trial Evaluating Nogapendekin Alfa Inbakicept in Combinatio
Phase 2 StartPhase 2 Start: Phase 2, Randomized, Open-Label Clinical Trial Evaluating Nogapendekin Alfa Inbakicept in Combinatio
Phase 2 StartPhase 2 Start: Open-Label, Single-Arm Phase 2 Study Of Nogapendekin Alfa Inbakicept, PD-L1 T-HaNK, And Bevacizumab
Phase 3 ReadoutPhase 3 Topline: Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Faile
Patent ExpiryPatent/Exclusivity Expiry: ABRAXANE
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.